1 Day
المصدر:
The Fiscal Times
The Fiscal Times
جاهز للتشغيل
جاهز للتشغيل
The FDA has approved Moderna’s new mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older. The vaccine received full approval for those aged 50-64 and accelerated approval for seniors aged 65 and older, with data showing it is safe and effective. This development introduces a new flu shot option using innovative technology, which may improve response to evolving flu strains.
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading